GeneDx Holdings Corp.

GeneDx Holdings Corp., formed through the combination of blank-check company Casdin & Churchill Acquisition Corp. (Nasdaq: CMLF) with genomic testing laboratory GeneDx, filed an S-1 registration statement with the SEC on August 4, 2021. The SPAC, which completed its IPO in early 2021, was co-sponsored by Casdin Capital and Churchill Capital and targeted the genomics and rare-disease diagnostics sector. The transaction brought together GeneDx, a subsidiary of OPKO Health specializing in hereditary and rare-disease genetic testing, with CMLF's public vehicle; the merger ultimately closed in 2022, yielding a publicly traded genomics company. Visit SpacDesk and sign up for full filings, timeline data, and deal analytics on this and every active SPAC.